Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core Operating Income: $6,036M in Q3 2026, up 10.5% from a year earlier. That is the highest of the 11 quarters on record here.
Latest, Q3 2026
6,036
Period ended Sep 30, 2026
Change on a year earlier
+10.5%
5,460 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“|| Core operating income | 6 036 | 5 460 | 11 | 10 | 16 873 | 16 960 | -1 | -2”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K (Non-IFRS disclosures) & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Operating Income ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 6,036 | +10.5% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 5,940 | +0.3% | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 4,897 | -12.2% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,929 | +1.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 5,460 | +6.1% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2025 | Jun 30, 2025 | 5,925 | +19.6% | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 5,575 | +22.9% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,859 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2024 | Sep 30, 2024 | 5,145 | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,953 | – | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,537 | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
Breakdown
What makes up core Operating Income
- Core Operating Income Growth at Constant Currencies (% cc)10.0% · Q3 2026
- Core Operating Income Growth in USD (% USD)11.0% · Q3 2026
- Currency Impact on Core Operating Income Growth (percentage points)1.0% · Q3 2026
- Core Operating Income Margin (%)41.6% · Q3 2026
- IFRS Operating Income Margin (%)12.7% · Q3 2026
- Core Gross Profit12,151 · Q3 2026
- Core Cost of Goods Sold-2,878 · Q3 2026
- Core R&D-2,787 · Q3 2026
- Core SG&A-3,078 · Q3 2026
- Core Income Before Taxes5,551 · Q3 2026
- Core Income Taxes-896 · Q3 2026
- Core Net Income4,655 · Q3 2026
- Core EPS (USD/share)2.46 · Q3 2026
Cite this data
StockData. (2026). Novartis Core Operating Income ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-operating-income
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.